IDO1/Keytruda combo trial fails in melanoma, page-5

  1. 13,164 Posts.
    lightbulb Created with Sketch. 1214
    Hi,
    I think Merck will end up needing to raise their offer.
    There has been enough shares traded to form a block for a more competitive offer.
    Daveys post has just reinforced the fact Cavatak is the leader in the field.
    Lepu could change there mind as well if they smell a dollar more.
    All IMO.
    Aloha.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.